What is the incidence of hyperprolactinemia in patients treated with fluvoxamine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hyperprolactinemia with Fluvoxamine: Incidence and Clinical Significance

The specific incidence of hyperprolactinemia with fluvoxamine is not well-established in the available evidence, but appears to be uncommon based on FDA labeling data and limited research studies.

Available Evidence on Fluvoxamine and Prolactin

The FDA drug label for fluvoxamine does not list hyperprolactinemia as a reported adverse event in controlled clinical trials involving 1,087 patients with OCD and depression 1. The comprehensive adverse event tables documenting events occurring at ≥1% frequency make no mention of elevated prolactin levels or hyperprolactinemia 1.

However, one small research study provides some insight: In 8 healthy volunteers given fluvoxamine 25-200 mg/day over 4 weeks, 2 out of 8 subjects (25%) developed substantial increases in serum prolactin levels (up to 35 μg/L) 2. Notably, these two individuals had higher baseline platelet 5-HT2A receptor density (Bmax 32.7 vs 23.1 fmol/mg protein), suggesting a potential biological predisposition 2.

Context: SSRIs and Hyperprolactinemia

While the Endocrine Society guidelines extensively discuss medication-induced hyperprolactinemia, they focus primarily on antipsychotics, which cause hyperprolactinemia through dopamine D2 receptor antagonism 3. For comparison:

  • Risperidone: 50-100% incidence 3
  • Typical antipsychotics: 40-90% incidence 3
  • Verapamil: 8.5% incidence 3

SSRIs like fluvoxamine are not prominently featured in these guidelines as major causes of hyperprolactinemia, suggesting they are less problematic than antipsychotics.

Clinical Implications

If hyperprolactinemia occurs with fluvoxamine:

  1. Verify the diagnosis: Measure serum prolactin (typically 25-100 μg/L with medication-induced cases, though can be higher) 3

  2. Assess for symptoms: Look for galactorrhea, menstrual irregularities in women, erectile dysfunction and decreased libido in men, and potential bone density concerns with prolonged hypogonadism 3

  3. Management approach per Endocrine Society guidelines 3:

    • Asymptomatic patients: No treatment necessary
    • Symptomatic patients or those with hypogonadal symptoms/low bone mass:
      • First option: Discontinue fluvoxamine if clinically feasible
      • Second option: Switch to an alternative antidepressant without prolactin effects
      • Third option: Consider estrogen/testosterone replacement for hypogonadism
      • Dopamine agonists are generally not recommended for medication-induced hyperprolactinemia due to limited efficacy (normalizes prolactin in only 75% of cases) and potential adverse effects 3

Key Caveats

  • The 25% incidence from the research study 2 may overestimate real-world risk, as it involved healthy volunteers at higher doses with intensive monitoring
  • Individual susceptibility may relate to 5-HT2A receptor status, though this is not clinically testable in routine practice
  • Prolactin levels typically take 3 days to normalize after drug discontinuation 3

Bottom line: Fluvoxamine-induced hyperprolactinemia appears uncommon compared to antipsychotics, but can occur. Monitor for symptoms rather than routine prolactin screening, and manage conservatively by discontinuing or switching the medication when symptomatic hyperprolactinemia develops.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.